PMID- 29458367
OWN - NLM
STAT- MEDLINE
DCOM- 20180830
LR  - 20221207
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 16
IP  - 1
DP  - 2018 Feb 20
TI  - The rs1024611 in the CCL2 gene and risk of gynecological cancer in Asians: a 
      meta-analysis.
PG  - 34
LID - 10.1186/s12957-018-1335-4 [doi]
LID - 34
AB  - BACKGROUND: The -2518A/G (rs1024611) polymorphism of the CCL2 (C-C motif 
      chemokine ligand 2), also known as MCP-1 (monocyte chemotactic protein-1) gene, 
      has been reported to be associated with increased gynecological cancer risk, but 
      the results are conflicting. METHODS: In this analysis, 1089 cases and 1553 
      controls from six publications were used to investigate the association between 
      CCL2-2518A/G (rs1024611) polymorphism and the risk of gynecological cancer with a 
      meta-analytic approach. Studies published on EBSCO, EMBASE, Web of Science, 
      PubMed, SpringerLink, ScienceDirect, Weipu, and CNKI databases were identified 
      (last update was on November 3, 2015). Six articles focused on the association 
      between CCL2-2518A/G (rs1024611) polymorphism, and gynecological cancer risk was 
      selected and data were extracted. The cancer type included endometrial cancer 
      (n = 1), breast cancer (n = 2), ovarian cancer (n = 2), and cervical cancer 
      (n = 1). All statistical analyses were performed using the STATA version 12.0 
      software. RESULTS: The meta-analysis showed that CCL2-2518A/G (rs1024611) 
      polymorphism is associated with risk of gynecological cancer (GG vs AG + AA, 
      OR = 1.55, 95%CI = 1.07-2.24, P < 0.05; AA vs GG, OR = 0.59 95%CI = 0.38-0.92, 
      P < 0.05). Notably, the subgroup analysis demonstrated that the genotype AA is 
      associated with a reduced gynecological cancer risk in Asians, but an increased 
      risk when compared to AG in Europeans. CONCLUSIONS: Our data demonstrated the 
      CCL2-2518A/G (rs1024611) polymorphism is significantly associated with risk of 
      gynecological cancer, and the association differs by ethnicity.
FAU - He, Shuying
AU  - He S
AD  - Department of Obstetrics and Gynecology, China XD Group Hospital, No. 97 Fengdeng 
      Road, Lianhu District, Xi'an, China.
FAU - Zhang, Xiuzhen
AU  - Zhang X
AUID- ORCID: 0000-0003-3065-039X
AD  - 1st Department, Gynecology Oncology, Shaanxi Provincial Tumor Hospital, No. 309, 
      Yantaxi Road, Xi'an, 710061, China. huxf2003@sina.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20180220
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Asian People/*genetics
MH  - Case-Control Studies
MH  - Chemokine CCL2/*genetics
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Genital Neoplasms, Female/etiology/*genetics
MH  - Humans
MH  - *Polymorphism, Single Nucleotide
MH  - Risk Factors
PMC - PMC5819160
OTO - NOTNLM
OT  - CCL2
OT  - CCL2-2518A/G
OT  - Gynecological cancer
OT  - Meta-analysis
OT  - Polymorphism
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This study was approved by the Ethics 
      Committee of China XD Group Hospital. CONSENT FOR PUBLICATION: N/A COMPETING 
      INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S 
      NOTE: Springer Nature remains neutral with regard to jurisdictional claims in 
      published maps and institutional affiliations.
EDAT- 2018/02/21 06:00
MHDA- 2018/08/31 06:00
PMCR- 2018/02/20
CRDT- 2018/02/21 06:00
PHST- 2017/08/22 00:00 [received]
PHST- 2018/02/05 00:00 [accepted]
PHST- 2018/02/21 06:00 [entrez]
PHST- 2018/02/21 06:00 [pubmed]
PHST- 2018/08/31 06:00 [medline]
PHST- 2018/02/20 00:00 [pmc-release]
AID - 10.1186/s12957-018-1335-4 [pii]
AID - 1335 [pii]
AID - 10.1186/s12957-018-1335-4 [doi]
PST - epublish
SO  - World J Surg Oncol. 2018 Feb 20;16(1):34. doi: 10.1186/s12957-018-1335-4.